Why Is Sarepta Therapeutics (SRPT) Down 1.2% Since Last Earnings Report?Zacks Investment Research • 03/31/22
Sarepta Therapeutics Announces Fifth Year of Route 79, The Duchenne Scholarship ProgramGlobeNewsWire • 03/08/22
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 03/01/22
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2021 Financial Results and Recent Corporate Developments on March 1, 2022GlobeNewsWire • 02/22/22
Sarepta Therapeutics' Gene Therapy SRP-9001 Shows Statistically Significant Functional Improvements Compared to Pre-specified Matched External Control in Part 2 of Study SRP-9001-102 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 01/10/22
Sarepta Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/22
Why Is Sarepta Therapeutics (SRPT) Down 4.4% Since Last Earnings Report?Zacks Investment Research • 12/03/21
Moore Kuehn, PLLC Encourages Investors of Sarepta Therapeutics, Inc. to Contact Law FirmNewsfile Corp • 11/30/21
Wall Street Analysts See a 60% Upside in Sarepta Therapeutics (SRPT): Can the Stock Really Move This High?Zacks Investment Research • 11/29/21
Sarepta Therapeutics Names Louise Rodino-Klapac, Ph.D., Head of Research and DevelopmentGlobeNewsWire • 11/17/21
Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Sarepta Therapeutics (SRPT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/03/21